Skip to content
Screener

Jazz Pharmaceuticals JAZZ Modeyso — Revenue from Contract with Customer, Excluding Assessed Tax

Other product segments

Xywav
$408.2M+18.4%
Epidiolex/Epidyolex
$249.8M+14.7%
Rylaze/Enrylaze
$103.7M+10.1%
Zepzelca
$101M+60.3%
Defitelio/defibrotide
$47.4M+16.5%
High-sodium oxybate AG royalty revenue
$36.3M-25.8%
Xyrem
$31.2M-16.1%
Vyxeos
$26.6M-9.8%
Ziihera
$13.3M+565%
Other royalty and contract revenues
$9.76M+27.5%
Other
$2.7M-73.8%

Similar metrics at other companies

Entergy logo
ETROther revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$36.28M-41.5%
CarMax logo
KMXService revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$24.2M+24.1%
Travel + Leisure logo
TNLAncillary Revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$0-100%
Travel + Leisure logo
TNLTransaction Revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$109M-6.8%
Restaurant Brands International logo
QSRProperty revenues — Revenue from Contract with Customer, Excluding Assessed Tax
$0-100%
Northern Trust logo
NTRSOther — Revenue from Contract with Customer, Excluding Assessed Tax
$68.6M+8.2%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$16.98B+165%
Enterprise value$21.71B+104%
P/S3.8×+2.3×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001232524-26-000025
Line itemThree Months Ended March 31, 20262025
Rylaze/Enrylaze103.794.2
Zepzelca101.063.0
Defitelio/defibrotide47.440.7
Modeyso41.4—
Vyxeos26.629.5
Ziihera13.32.0
Oncology333.4229.4
Other12.710.3

Item 1.Financial Statements

FAQ

What is Jazz Pharmaceuticals's modeyso — revenue from contract with customer, excluding assessed tax?
Jazz Pharmaceuticals (JAZZ) reported modeyso — revenue from contract with customer, excluding assessed tax of $41.4M in Q1 2026.
What does modeyso — revenue from contract with customer, excluding assessed tax mean?
This metric represents the total gross revenue generated from the sale of the Modeyso product line, net of any sales-related taxes. It reflects the commercial performance and market adoption of this specific therapeutic asset within the company's broader neuroscience or oncology portfolio. This figure is critical for assessing the revenue contribution and growth trajectory of the product following its commercial launch or acquisition.

Ask your AI about Jazz Pharmaceuticals's modeyso — revenue from contract with customer, excluding assessed tax.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude